Reuters logo
BRIEF-Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer
November 28, 2017 / 1:09 PM / 17 days ago

BRIEF-Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer

Nov 28 (Reuters) - Pfizer Inc:

* MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN GASTRIC 300 STUDY IN PATIENTS WITH PRE-TREATED ADVANCED GASTRIC CANCER

* MERCK KGAA- ‍PHASE III JAVELIN GASTRIC 300 TRIAL DID NOT MEET ITS PRIMARY ENDPOINT ​

* MERCK KGAA- ‍SAFETY PROFILE OF AVELUMAB WAS CONSISTENT WITH THAT OBSERVED IN OVERALL JAVELIN CLINICAL DEVELOPMENT PROGRAM​

* MERCK KGAA - ‍OUTCOME OF JAVELIN GASTRIC 300 DOES NOT HAVE ANY IMPACT ON CURRENT AVELUMAB APPROVALS​

* MERCK KGAA - ‍JAVELIN GASTRIC 300 DATA WILL BE FURTHER EXAMINED TO BETTER UNDERSTAND RESULTS; WILL BE SUBMITTED FOR PRESENTATION AT MEDICAL CONGRESS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below